AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.13 |
Market Cap | 56.50M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.07 |
PE Ratio (ttm) | -1.99 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.5 |
Volume | 86,407 |
Avg. Volume (20D) | 284,729 |
Open | 2.15 |
Previous Close | 2.08 |
Day's Range | 2.10 - 2.20 |
52-Week Range | 0.89 - 5.33 |
Beta | undefined |
About GANX
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing s...
Analyst Forecast
According to 4 analyst ratings, the average rating for GANX stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 252.11% from the latest price.
Next Earnings Release
Analysts project revenue of $30.00K, reflecting a n/a YoY growth and earnings per share of -0.17, making a -41.38% decrease YoY.